A 15 amino acid peptide derived from human gastric juice, widely researched for its tissue-healing and cytoprotective properties.

A synthetic version of the naturally occurring peptide Thymosin Beta-4, studied for tissue repair, inflammation reduction, and vascular remodeling.

The copper-free parent tripeptide of GHK-Cu, studied independently for wound healing, gene expression modulation, and anti-inflammatory activity without requiring copper chelation.

A peptide bioregulator from the Khavinson Institute targeting connective tissue — cartilage, ligaments, and joints — for repair and age-related degeneration.

A long-acting GHRH analogue with a Drug Affinity Complex that extends its half-life dramatically, allowing weekly dosing for sustained GH elevation.

A highly selective GH secretagogue and ghrelin receptor agonist known for clean GH release without significant cortisol or prolactin stimulation.

A 29-amino acid truncated analogue of endogenous GHRH, FDA-approved for pediatric GHD and widely researched for anti-aging and body composition.

A potent GH secretagogue with strong ghrelin receptor activity, producing significant GH pulses with some cortisol and prolactin elevation.

One of the original GH secretagogue peptides, notable for strong hunger stimulation alongside robust GH release.

The most potent GH secretagogue peptide available, with additional direct cardiac and anti-fibrotic research applications.

A modified fragment of human growth hormone specifically targeting fat metabolism without the growth-promoting or diabetogenic effects of full GH.

A GLP-1 receptor agonist with FDA approval for type 2 diabetes and obesity, demonstrating unprecedented weight loss results in clinical trials.

A dual GIP/GLP-1 receptor agonist with FDA approval showing up to 22% weight loss — superior to semaglutide in head-to-head trials.

A triple GIP/GLP-1/glucagon receptor agonist in Phase III trials, showing over 24% weight loss — potentially the most powerful metabolic peptide in development.

A once-daily GLP-1 receptor agonist with FDA approval for T2D and obesity, the predecessor to semaglutide with strong clinical evidence.

The first GLP-1 receptor agonist approved by the FDA for T2D, derived from Gila monster venom with strong glucose-lowering and weight management effects.

A synthetic heptapeptide analogue of tuftsin with anxiolytic, nootropic, and immune-modulating properties developed in Russia.

A synthetic heptapeptide based on ACTH fragment with potent nootropic, neuroprotective, and stroke-recovery properties developed in Russia.

An extremely potent nootropic peptide (10 million times more potent than BDNF) that enhances synaptogenesis, with promising research in Alzheimer's models.

A naturally occurring neuropeptide that regulates sleep-wake cycles, stress response, and has shown longevity-associated effects in animal research.

Synthetic octapeptide fragment of spadin that blocks TREK-1 potassium channels, producing rapid antidepressant and cognitive effects in preclinical models.

An acetylated derivative of Semax with enhanced potency and potentially more consistent activity compared to the parent compound, studied for cognitive enhancement and neuroprotection.

A naturally occurring copper complex peptide with potent wound healing, anti-aging, and regenerative properties studied extensively for skin and tissue applications.

A synthetic alpha-MSH analogue with FDA-orphan drug approval for erythropoietic protoporphyria, producing skin darkening through melanin stimulation.

A cyclic alpha-MSH analogue with potent melanogenic, sexual arousal, and appetite-suppressing effects through broad melanocortin receptor activation.

A synthetic acetyl hexapeptide that mimics the N-terminus of SNAP-25, inhibiting neuromuscular signalling to relax facial muscles and reduce expression-line wrinkles — widely used in cosmetic skincare.

A palmitoylated pentapeptide and one of the most widely studied and used cosmetic anti-aging peptides, functioning as a matrikine to stimulate collagen and extracellular matrix production.

An extended octapeptide analogue of Argireline that adds additional SNARE complex inhibition domains, studied for greater potency in reducing expression-line wrinkles compared to Argireline alone.

A mitochondrial-derived peptide that regulates metabolic homeostasis, glucose uptake, and has shown remarkable longevity effects in animal studies.

A synthetic tetrapeptide based on Epithalamin with telomerase activation and antioxidant properties showing remarkable longevity effects in multiple animal species.

A mitochondria-derived peptide encoded in the 16S rRNA region with remarkable cytoprotective, anti-apoptotic, and longevity-associated properties.

A cardiolipin-targeted mitochondria-protective peptide showing remarkable results in heart failure, AMD, and mitochondrial disease research.

A synthetic dipeptide (Lys-Glu) derived from the thymus with studied immunomodulatory and longevity-associated properties, developed as part of the Russian bioregulator peptide program.

A tetrapeptide bioregulator (Lys-Glu-Asp-Ala) from the Khavinson Institute studied for cardiovascular protection, immune restoration, and anti-aging effects.

A 28-amino acid peptide derived from the thymus with potent immunomodulatory effects approved in multiple countries for hepatitis and cancer supportive care.

The only human cathelicidin antimicrobial peptide, with broad-spectrum antimicrobial activity, immunomodulation, and wound-healing properties.

Polypeptide extract from the thymus gland that broadly restores immune function and extends longevity in research.

A 28-amino acid neuropeptide and potent immunomodulator with anti-inflammatory, vasodilatory, and neuroprotective properties, with an extensive clinical research history in autoimmune, inflammatory, and pulmonary conditions.

FDA-approved melanocortin receptor agonist for hypoactive sexual desire disorder in premenopausal women, with off-label research in men.

An endogenous neuropeptide and master regulator of the HPG axis, GnRH release, and reproductive function with significant clinical research interest.

The endogenous hypothalamic hormone that regulates the HPG axis through pulsatile GnRH receptor signaling, used in fertility and hormonal research.

Engineered D-retro-inverso peptide that selectively induces apoptosis in senescent cells, reversing aging hallmarks in mice.

Endogenous heptapeptide that counterbalances Angiotensin II — cardioprotective, anti-fibrotic, and vasodilatory.

A chimeric anticancer peptide containing the MDM2-binding domain of p53 fused to a membrane-targeting sequence, studied for selective cancer cell killing via surface MDM2 binding and membrane disruption.

An FDA-approved synthetic analogue of a peptide toxin from the cone snail Conus magus, delivered intrathecally for severe chronic pain refractory to other treatments — the first approved conotoxin therapeutic.